quinazoline-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines

Quinazoline-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines are a novel class of small molecule compounds created by hybridizing the pharmacophore scaffolds of quinazoline and [1,2,4]triazolo[3,4-b][1,3,4]thiadiazine. These compounds have been specifically designed and synthesized as inhibitors of epidermal growth factor receptor (EGFR) with intended use as anticancer agents, particularly for breast cancer. Lead compounds, notably 6i and 6k, demonstrated significant in vitro cytotoxic activity against various breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-468), with compound 6i surpassing the established EGFR inhibitor erlotinib in potency by EGFR inhibition assay. Molecular docking studies and drug likeness analyses support their EGFR-targeted mechanism and therapeutic potential. Structure-activity relationship exploration has focused on substituent effects for further optimization. These compounds are currently at a preclinical research stage and have not been approved as pharmaceuticals[1][3][4].